Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Syprol 10mg/5ml oral solution
0204000R0BVABCX
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 40mg/5ml oral solution
0204000R0BVADDB
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 50mg/5ml oral solution
0204000R0BVACCY
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syprol 5mg/5ml oral solution
0204000R0BVAACW
|
Syprol | Propranolol hydrochloride | Cardiovascular System | No data available |
|
Syrup
091101000AABQBQ
|
Generic compound preparation BNF 0911010 | Other amino acidandnutritional agent preparations | Nutrition and Blood | No data available |
|
Syrup unpreserved
091101000AACDCD
|
Generic compound preparation BNF 0911010 | Other amino acidandnutritional agent preparations | Nutrition and Blood | No data available |
|
Syscor MR 10 tablets
0206020W0BBAAAA
|
Syscor | Nisoldipine | Cardiovascular System | No data available |
|
Syscor MR 20 tablets
0206020W0BBABAB
|
Syscor | Nisoldipine | Cardiovascular System | No data available |
|
Syscor MR 30 tablets
0206020W0BBACAC
|
Syscor | Nisoldipine | Cardiovascular System | No data available |
|
System 4 multi-layer compression bandage kit 18cm-25cm ankle circumference
20020201050
|
System 4 multi-layer compression bandage kit 18cm-25cm ankle circumference | Arm Sling/Bandages | Dressings | No data available |
|
System 4 multi-layer compression bandage kit 18cm-25cm ankle circumference (4 components)
20020201051
|
System 4 multi-layer compression bandage kit 18cm-25cm ankle circumference (4 components) | Arm Sling/Bandages | Dressings | No data available |
|
Tabphyn MR 400microgram capsules (Kyowa Kirin)
0704010U0BFAAAA
|
Tabphyn | Tamsulosin hydrochloride | Obstetrics, Gynaecology and Urinary-Tract Disorders | No data available |
|
Tacni 0.5mg capsules
0802020T0BGAAAF
|
Tacni | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacni 1mg capsules
0802020T0BGABAB
|
Tacni | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacni 5mg capsules
0802020T0BGACAA
|
Tacni | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 0.0001% mouthwash
0802020T0AAAXAX
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 25mg/5ml oral liquid
0802020T0AAASAS
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 2mg suppositories
0802020T0AABIBI
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 2mg/5ml oral suspension
0802020T0AAAKAK
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 500micrograms/5ml oral suspension
0802020T0AAARAR
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 5mg/1ml solution for infusion ampoules
0802020T0AAACAC
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 750microgram modified-release tablets
0802020T0AABDBD
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 800micrograms/5ml oral solution
0802020T0AABABA
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tacrolimus 900micrograms/5ml oral suspension
0802020T0AABBBB
|
Tacrolimus (Systemic) | Tacrolimus | Malignant Disease and Immunosuppression | No data available |
|
Tadomon 250mg prolonged-release tablets
0407020AGBDAEAG
|
Tadomon | Tapentadol | Central Nervous System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.